title: Worldwide genetic variability of the Duffy binding protein: insights into Plasmodium vivax vaccine development.
abstract: The dependence of Plasmodium vivax on invasion mediated by Duffy binding protein (DBP) makes this protein a prime candidate for development of a vaccine. However, the development of a DBP-based vaccine might be hampered by the high variability of the protein ligand (DBP(II)), known to bias the immune response toward a specific DBP variant. Here, the hypothesis being investigated is that the analysis of the worldwide DBP(II) sequences will allow us to determine the minimum number of haplotypes (MNH) to be included in a DBP-based vaccine of broad coverage. For that, all DBP(II) sequences available were compiled and MNH was based on the most frequent nonsynonymous single nucleotide polymorphisms, the majority mapped on B and T cell epitopes. A preliminary analysis of DBP(II) genetic diversity from eight malaria-endemic countries estimated that a number between two to six DBP haplotypes (17 in total) would target at least 50% of parasite population circulating in each endemic region. Aiming to avoid region-specific haplotypes, we next analyzed the MNH that broadly cover worldwide parasite population. The results demonstrated that seven haplotypes would be required to cover around 60% of DBP(II) sequences available. Trying to validate these selected haplotypes per country, we found that five out of the eight countries will be covered by the MNH (67% of parasite populations, range 48-84%). In addition, to identify related subgroups of DBP(II) sequences we used a Bayesian clustering algorithm. The algorithm grouped all DBP(II) sequences in six populations that were independent of geographic origin, with ancestral populations present in different proportions in each country. In conclusion, in this first attempt to undertake a global analysis about DBP(II) variability, the results suggest that the development of DBP-based vaccine should consider multi-haplotype strategies; otherwise a putative P. vivax vaccine may not target some parasite populations.
authors.affiliation: Laboratory of Malaria, Centro de Pesquisa Rene Rachou/Fiocruz, Belo Horizonte, Brazil.
authors.forename: Taís
authors.initials: T
authors.lastname: Nóbrega de Sousa
authors.forename: Luzia Helena
authors.initials: LH
authors.lastname: Carvalho
authors.forename: Cristiana Ferreira
authors.initials: CF
authors.lastname: Alves de Brito
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology*; D001499:Bayes Theorem; D016000:Cluster Analysis; D014644:Genetic Variation; D006239:Haplotypes; D017780:Malaria Vaccines / Q000276:immunology*; D010966:Plasmodium vivax / Q000276:immunology*; D011110:Polymorphism, Genetic; D015800:Protozoan Proteins / Q000276:immunology*; D011956:Receptors, Cell Surface / Q000276:immunology*
chemical_list: D000953:Antigens, Protozoan; C066001:Duffy antigen binding protein, Plasmodium; D017780:Malaria Vaccines; D015800:Protozoan Proteins; D011956:Receptors, Cell Surface